fda glp‑1 compounding restrictions
Fix Prescription Weight‑Loss Pricing Myth
Only 2% of every semaglutide or tirzepatide prescription in the United States was once a compounded version, but recent FDA restrictions have eliminated most of these low-cost options. The result is a clearer pricing landscape, though patients may see higher out-of-pocket costs. (Hims & Hers) Medical Disclaimer: This article is